North America Bioreactors Market growth was valued at USD 1.8 billion in 2019 and is expected to witness over 13.5% CAGR from 2020 to 2026.
Bioreactors are a vessels in which biological processing is conducted with optimum external environment. The biological system in bioreactors involves various microorganisms, enzymes, plant cells, animal cells and tissues. Adoption of advanced technology has led to development of various types of bioreactors considering the biological system that is widely equipped in biopharmaceutical and biotechnology industry.
Get more details on this report - Request Free Sample PDF
Recent developments in healthcare industry has led to adoption of various advanced equipment for better bioprocessing and large production. Growing incidence of various chronic disorders and infectious diseases have affected millions of people in the North America. According to the Centres for Disease Control and Prevention (CDC), around 83% of the children aged between 19-35 months are receiving vaccination for tetanus, diphtheria and pertussis. Thus, production of large number of crucial medicines will further increase the use of bioreactors in the biopharmaceutical industry. Moreover, improved flexibility, scalability of operations and quality of bioreactors will further drive its adoption rate, thereby augmenting market growth in the region.
North America Market, By Product Type
Reusable bioreactors segment held around USD 1.5 billion revenue in 2019. High segmental value is attributable to various benefits offered by reusable bioreactors such as cost effectiveness, mass production and easy storage of hot and fluid materials. Owing to increasing research and development activities and growing demand for vaccines and monoclonal antibodies, reusable bioreactors are being widely used in the pharmaceutical industries for mass production. Therefore, aforementioned factors will drive the reusable bioreactors market growth in the region.
North America Market, By Cell
Mammalian cells segment was valued at over USD 1.2 billion in 2019. Biologics and biopharmaceutical industries are growing in the region with presence of major market players. Mammalian cells are widely used in research and development activities for the manufacture of biologics. Moreover, rising awareness regarding demand for personalized and orphan drugs will also drive the adoption of mammalian cells, thus positively impacting the segment growth in the near future.
North America market, By Molecule
Monoclonal antibodies (mAbs) segment accounted for market share of 33.8% in 2019 and is expected to show similar growth during forecast period. With growing incidence of cancer and various immune disorders in North America, monoclonal antibodies will witness a surge in the usage for therapeutic products based on monoclonal antibodies. Prostate, colorectal and lung cancer accounted for 43% of the total cancer cases diagnosed in men. Thus, in order to reduce the cancer burden, mAbs are being widely used by the biotechnology and biopharmaceutical companies, thus driving the segment growth.
North America Market, By End-use
R&D organizations segment accounted for substantial share in 2019 and is expected to witness lucrative growth up to 2026. Ongoing new product development, clinical trials and development of new technologies such as cell line development, gene therapy and stem cells among others has fostered the growth of R&D organizations in the region. Additionally, growing research and development expenditure by the government and funding for new drug development will further contribute to the segment growth.
North America Market, By Country
U.S bioreactors market was valued at over USD 1.5 billion by 2019. Owing to increasing use of single-use bioreactors in biopharmaceutical industry and rising spending on research and development activities, bioreactors market will witness rapid growth. According to the U.S. Government Accountability Office (GAO, 2017), key players invested around USD 89 billion on drug development, while USD 28 billion was funded by U.S. federal government. Furthermore, rising burden of chronic disorders and infectious diseases such as COVID-19 pandemic has surged the demand for vaccines, thus increasing the market growth potential.
Competitive Market Share
Some of the major industry players involved in North America bioreactors market include Cytiva, Merck Group, Sartorius Stedim Biotech Group, and Thermo Fischer among others. The key players are undertaking various strategies such as collaborations and mergers & acquisitions to sustain market competition and explore the untapped business potential. For instance, in March 2020, Danaher announced the complete acquisition of biopharma business of General Electric Life Sciences, called CYTIVA bioreactors. This strategy will help the company in setting footprint in bioreactors market.
Use of bioreactors has been persistent since early 19th century. Large scale bioreactors have been widely used in pharmaceutical and food & beverage industry. Since the importance of aseptic conditions was recognised, various technological advancements were done to achieve sterile conditions. In 1946, first company was opened in New Brunswick, U.S.A. as New Brunswick Tool & Die Company. As adoption of technologically advanced products paved its way, NBS introduced first benchtop bioreactors in 1980s for animal cell culture. Since last 20 years, North America has become a global platform for biotechnology and biopharmaceutical company. With ongoing research on monoclonal antibodies, gene therapy and stem cells among others the demand for bioreactors has escalated tremendously, thereby positively impacting its market growth.